Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Strong Sell

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Sell

C

Ionis Pharmaceuticals, Inc. Common Stock (IONS)

Pharmaceutical Preparations

https://www.ionispharma.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

2855 GAZELLE COURT
CARLSBAD, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/17/1991

Market Cap

6,847,061,130

Shares Outstanding

143,470,000

Weighted SO

143,472,119

Total Employees

N/A

Upcoming Earnings

08/14/2024

Similar Tickers

ARWR --.--%

BMRN --.--%

INCY --.--%

APLS --.--%

VKTX --.--%

ICPT --.--%

TERN --.--%

AKRO --.--%

Beta

0.3980

Last Div

0.0000

Range

35.95-54.44

Chg

0.1650

Avg Vol

1320335

Mkt Cap

6847061130

Exch

NASDAQ

Country

US

Phone

760 931 9200

DCF Diff

69.2535

DCF

-22.4585

Div Yield

0.0000

P/S

8.4194

EV Multiple

-25.9238

P/FV

25.9206

Div Yield %

0.0000

P/E

-18.7096

PEG

0.5386

Payout

0.0000

Current Ratio

7.6083

Quick Ratio

7.5145

Cash Ratio

0.9603

DSO

12.2343

DIO

463.7455

Op Cycle

475.9798

DPO

149.2323

CCC

326.7475

Gross Margin

0.9722

Op Margin

-0.4485

Pretax Margin

-0.4337

Net Margin

-0.4492

Eff Tax Rate

-0.0358

ROA

-0.1358

ROE

-1.1580

ROCE

-0.1529

NI/EBT

1.0358

EBT/EBIT

0.9670

EBIT/Rev

-0.4485

Debt Ratio

0.6728

D/E

6.8660

LT Debt/Cap

0.8701

Total Debt/Cap

0.8729

Int Coverage

-8.8081

CF/Debt

-0.1911

Equity Multi

10.2053

Rec Turnover

29.8343

Pay Turnover

2.4459

Inv Turnover

0.7871

FA Turnover

3.3489

Asset Turnover

0.3022

OCF/Share

-2.3704

FCF/Share

-2.5650

Cash/Share

14.2417

OCF/Sales

-0.4254

FCF/OCF

1.0821

CF Coverage

-0.1911

ST Coverage

-7.7884

CapEx Coverage

-12.1766

Div&CapEx Cov

-12.1766

P/BV

25.9206

P/B

25.9206

P/S

8.4194

P/E

-18.7096

P/FCF

-18.2887

P/OCF

-19.7564

P/CF

-19.7564

PEG

0.5386

P/S

8.4194

EV Multiple

-25.9238

P/FV

25.9206

DPS

0.0000

Latest Headlines (EST)

Benzinga Jan 22, 14:35 Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study Benzinga Jan 22, 14:35 Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study Benzinga Jan 18, 13:00 Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts Benzinga Dec 22, 12:04 Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential MarketWatch Dec 21, 20:43 Ionis, AstraZeneca get FDA approval for rare genetic disease treatment MarketWatch Dec 21, 20:43 Ionis, AstraZeneca get FDA approval for rare genetic disease treatment MarketWatch Dec 21, 20:43 Ionis, AstraZeneca get FDA approval for rare genetic disease treatment MarketWatch Dec 21, 20:43 Ionis, AstraZeneca get FDA approval for rare genetic disease treatment MarketWatch Dec 21, 20:43 Ionis, AstraZeneca get FDA approval for rare genetic disease treatment MarketWatch Dec 21, 20:43 Ionis, AstraZeneca get FDA approval for rare genetic disease treatment Benzinga Dec 19, 14:23 Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach Seeking Alpha Nov 30, 00:50 Tracking Tweedy, Browne Portfolio - Q3 2023 Update Benzinga Nov 17, 07:00 Where Ionis Pharmaceuticals Stands With Analysts

Revenue Product Segmentation